Poulet, Geoffroy
Hulot, Jean-Sébastien
Blanchard, Anne
Bergerot, Damien
Xiao, Wenjin
Ginot, Frederic
Boutonnet-Rodat, Audrey
Justine, Abdelli
Beinse, Guillaume
Geromel, Vanna
Pellegrina, Laurence
Azizi, Michel
Laurent-Puig, Pierre
Benhaim, Leonor
Taly, Valerie
Funding for this research was provided by:
Association Nationale de la Recherche et de la Technologie
Eurofins Viracor BioPharma
Article History
Received: 11 July 2023
Accepted: 19 November 2023
First Online: 7 December 2023
Competing interests
: VT: Honoraria from Raindance Technologies and Boerhinger Ingehleim; cofounder emulseo; board emulseo. PLP: Honoraria and board: Amgen, Merck-Serono, Boehringer Ingelheim, Sanofi, Roche, Lilly. AB: Honoraria and board: Amgen. JSH: speaker, advisory board or consultancy fees from Amgen, Astra Zeneca, Bayer, Bristol-Myers Squibb, Novartis, Novo Nordisk, Vifor Pharma, all unrelated to the present work. GP: Eurofins-Biomnis employee. PL: Eurofins-Biomnis employee. VG: Eurofins-Biomnis employee. AB (Dr Audrey Boutonnet): ADELIS employee. FG: ADELIS employee. The other authors declare no competing interests.